Predictive Oncology Files 8-K: Director & Officer Changes
Ticker: AGPU · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1446159
Sentiment: neutral
Topics: director-changes, officer-appointment, financial-statements
TL;DR
Predictive Oncology's 8-K shows director/officer changes and financial updates.
AI Summary
Predictive Oncology Inc. filed an 8-K on September 12, 2025, reporting events on September 9, 2025. The filing indicates changes related to the departure and election of directors, appointment of officers, and compensatory arrangements. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with financial disclosures, can indicate significant internal shifts that may affect future performance.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- September 9, 2025 (date) — Date of Earliest Event Reported
- September 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific changes occurred regarding directors and officers?
The filing indicates the departure of directors, election of new directors, and appointment of certain officers, along with details on compensatory arrangements.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated September 9, 2025.
When was this 8-K form filed with the SEC?
This Form 8-K was filed on September 12, 2025.
What are the previous names of Predictive Oncology Inc. mentioned in the filing?
Previous names include Precision Therapeutics Inc. (name change 20180314), Precision Therapeutic Inc. (name change 20180208), and Skyline Medical Inc. (name change 20130807).
What is the SIC code and industry for Predictive Oncology Inc.?
The SIC code is 3842, and the industry is ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-12 17:01:21
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share POAI NASDAQ Capital Market
Filing Documents
- f8k_090925.htm (8-K) — 22KB
- exh_101.htm (EX-10.1) — 22KB
- 0001171843-25-005890.txt ( ) — 214KB
- poai-20250909_lab.xml (EX-101.LAB) — 33KB
- poai-20250909_pre.xml (EX-101.PRE) — 22KB
- poai-20250909.xsd (EX-101.SCH) — 3KB
- f8k_090925_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2025, the Board of Directors (the "Board") of Predictive Oncology Inc. (the "Company"), upon the recommendation of the Compensation Committee of the Board, determined that it was appropriate to award restricted stock units ("RSUs") as a form of compensation for employees, consultants and directors, to be granted under the Company's 2024 Equity Incentive Plan. In connection therewith, the Board approved a form of Restricted Stock Unit Award Agreement. Consistent with the above determination, on September 9, 2025, upon the recommendation of the Compensation Committee, the Board approved the grant of 124,959 RSUs to Raymond F. Vennare, the Company's Chief Executive Officer and 97,000 RSUs to Josh Blacher, the Company's Interim Chief Financial Officer. Each RSU represents the right to receive one share of the Company's common stock upon vesting. The RSUs will vest in full on October 31, 2025, subject to continued service through the vesting date. The form of Restricted Stock Unit Award Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The foregoing description of the RSU grants to Messrs. Vennare and Blacher is qualified in its entirety by reference to the complete terms and conditions of the form of Restricted Stock Unit Award Agreement, incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 10.1 Form of Restricted Stock Unit Award Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: September 12, 2025 By: /s/ Josh Blacher Name: Josh Blacher Title: Interim Chief Financial Officer